Skip to main content
Article thumbnail
Location of Repository

Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: a systematic review

By Timothy J. England, Claire L. Gibson and Philip M.W. Bath


Background\ud Granulocyte-colony stimulating factor (G-CSF) shows promise as a treatment for stroke. This systematic review assesses G-CSF in experimental ischaemic stroke.\ud \ud Methods\ud Relevant studies were identified with searches of Medline, Embase and PubMed. Data were extracted on stroke lesion size, neurological outcome and quality, and analysed using Cochrane Review Manager using random effects models; results are expressed as standardised mean difference (SMD) and odds ratio (OR).\ud \ud Results\ud Data were included from 19 publications incorporating 666 animals. G-CSF reduced lesion size significantly in transient (SMD -1.63, p<0.00001) but not permanent (SMD -1.56, p=0.11) focal models of ischaemia. Lesion size was reduced at all doses and with treatment commenced within 4 hours of transient ischaemia. Neurological deficit (SMD -1.37, p=0.0004) and limb placement (SMD -1.88, p=0.003) improved with G-CSF; however, locomotor activity (>4 weeks post ischaemia) was not (SMD 0.76, p=0.35). Death (OR 0.27, p<0.0001) was reduced with G-CSF. Median study quality was 4 (range 0-7/8); Egger’s test suggested significant publication bias (p=0.001).\ud \ud Conclusions\ud G-CSF significantly reduced lesion size in transient but not permanent models of ischaemic stroke. Motor impairment and death were also reduced. Further studies assessing dose-response, administration time, length of ischaemia and long-term functional recovery are needed

Publisher: Elsevier
Year: 2009
OAI identifier:
Provided by: Nottingham ePrints

Suggested articles


  1. (2005). [Effects of granulocyte colonystimulating factor on focal cerebral ischemia-reperfusion injury in rats].
  2. 2007b) Observed that G-CSF and SCF pass through an intact blood-brain barrier in intact rats. No stroke induced.
  3. (2006). Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells.
  4. (2007). Administration of hematopoietic cytokines increases the expression of antiinflammatory cytokine (IL-10) mRNA in the subacute phase after stroke.
  5. (2006). An extended window of opportunity for G-CSF treatment in cerebral ischemia.
  6. (2006). Anti-apoptotic effect of granulocyte-colony stimulating factor after focal cerebral ischemia in the rat.
  7. (2005). Article in Chinese and unable to acquire to translate.
  8. (2003). Beneficial effect of pharmacological mobilization of bone marrow in experimental cerebral ischemia.
  9. (2007). Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats.
  10. (1997). Bias in meta-analysis detected by a simple, graphical test.
  11. (2009). Bone marrow stromal cells (BMSC), pre-treated with G-CSF, transplanted into mouse stroke brain, enhanced motor function earlier than mice treated with ‘non-treated’ BMSC.
  12. (2007). Brain repair by hematopoietic growth factors in a rat model of stroke.
  13. (2007). Colony stimulating factors (blood growth factors) are promising but unproven for treating stroke.
  14. (2006). Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic Reviews.
  15. (2009). Compared neurotransmitter profile in rats subjected to photothrombotic ischaemia treated with either GCSF or brain derived neurotrophic factor (BDNF). No infarct volumes or functional outcome measures.
  16. (2007). Decreased focal inflammatory response by GCSF may improve stroke outcome after transient middle cerebral artery occlusion in rats.
  17. (2009). Different postischemic protein expression of the GABA(A) receptor alpha2 subunit and the plasticity-associated protein MAP1B after treatment with BDNF versus G-CSF in the rat brain.
  18. (2007). Effect of G-CSF on global cerebral ischaemia. No long-term (2 weeks) protection seen in neurobehavioural studies.
  19. (2008). Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach.
  20. (2009). Endogenous brain protection by granulocytecolony stimulating factor after ischemic stroke. Experimental Neurology.
  21. (2006). Estrogens and experimental ischemic stroke: a systematic review.
  22. (2002). Excitatory amino acid antagonists for acute stroke (Cochrane Review). In:
  23. (2006). Fibronectin and neuroprotective effect of granulocyte colony-stimulating factor in focal cerebral ischemia.
  24. (2004). Functional recovery of stroke rats induced by granulocyte colony-stimulating factorstimulated stem cells.
  25. (2004). Functional recovery of stroke rats induced by granulocyte colony-stimulating factorstimulated stem cells.[see comment].
  26. (2003). Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes.
  27. (2007). G-CSF and rt-PA for the treatment of experimental embolic stroke. Cerebrovascular Diseases.
  28. (2007). G-CSF enhances stem cell proliferation in rat hippocampus after transient middle cerebral artery occlusion.
  29. (2006). G-CSF given in combination with SCF acutely and subacutely. Permanent MCAo model used. Reduction in infarct volume and enhanced functional recovery.
  30. (2008). G-CSF given in combination with SCF in a permanent MCAo mouse model. Treatment induced infarct volume reduction and enhanced angiogenesis.
  31. (2005). G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice.
  32. (2005). G-CSF suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice.
  33. (2009). Good laboratory practice: preventing introduction of bias at the bench.
  34. (2005). Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia.
  35. (2006). Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial.
  36. (2009). Granulocyte colony-stimulating factor protects the brain against experimental stroke via inhibition of apoptosis and inflammation.
  37. (2007). Granulocyte colonystimulating factor has a negative effect on stroke outcome in a murine model.
  38. (2008). Granulocyte stimulating factor attenuates hypoxic-ischemic brain injury by inhibiting apoptosis in neonatal rats.
  39. (2007). Granulocyte-colony stimulating factor inhibits apoptotic neuron loss after neonatal hypoxia-ischemia in rats.
  40. (2008). Granulocyte-colony stimulating factor inhibits neuronal apoptosis in a rat model of diabetic cerebral ischemia.
  41. (2006). Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092).
  42. (2007). Granulocytecolony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke.
  43. (2007). Hematopoietic growth factors pass through the blood-brain barrier in intact rats.
  44. (2007). How can we improve the preclinical development of drugs for stroke? Trends in Neurosciences.
  45. (1988). Independent regulation of M-CSF and G-CSF gene expression in human monocytes.
  46. (2008). Inhibited glutamate release by granulocyte-colony stimulating factor after experimental stroke.
  47. (1986). Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colonystimulating activity and prostaglandin E2.
  48. (2005). Magnetic resonance tracking of human CD34+ progenitor cells separated by means of immunomagnetic selection and transplanted into injured rat brain.
  49. (2005). Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord. Annals of the New York Academy of Sciences.
  50. (2008). Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of focal Cerebral Ischemia.
  51. (2003). Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke.
  52. (1986). Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.
  53. (2003). Neuroprotective effect of granulocyte colonystimulating factor after focal cerebral ischemia.
  54. (2006). Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice.
  55. (2005). Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review.
  56. (2007). NXY-059 for the treatment of acute ischemic stroke.
  57. (2007). Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats.
  58. (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
  59. (2009). Stem cells for enhancing recovery after stroke: a review.
  60. (2006). Stroke and neurovascular protection.
  61. (2009). Synergistic effects of granulocyte-colony stimulating factor on bone marrow stromal cell transplantation for mice cerebral infarct.
  62. (2008). The combination of granulocyte colony-stimulating factor and stem cell factor significantly increases the number of bone marrow-derived endothelial cells in brains of mice following cerebral ischemia.
  63. (2007). The effect of granulocyte-colony stimulating factor in global cerebral ischemia in rats.
  64. (2005). The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis.
  65. (2008). Therapeutic potential and possible risks of pleiotropic growth factors in ischemic stroke.
  66. (2002). Thrombolysis for acute ischaemic stroke (Cochrane Review). In:
  67. (2001). Tirilazad for acute ischaemic stroke. Cochrane Database of Systematic Reviews.
  68. (2005). Transplanted human bone marrow cells generate new brain cells.
  69. (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations.
  70. (1988). Vascular endothelial cells and granulopoiesis:
  71. (2005). week before and weekly for 5 weeks post ischaemia] 2, 24, 96 and 168 Schneider

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.